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I About this guide 
This short document aims to provide a summary of the main issues that people engaged 
in the implementation of quality standards in the area of drug demand reduction need 
to consider. There are many sources of more detailed information and guidance on 
implementing standards. This guide seeks not to duplicate or replace them but instead to 
act as an introduction, providing links to the wider literature and presenting the key issues 
for those planning and managing these processes. Further reading and sources of more 
detailed information are provided at the end of this guide. There is also no single correct 
way to implement quality assurance processes, and the choice of approach depends on 
many factors, including timing, objectives and the availability of resources. 
This publication is designed to assist people in choosing the best approach to suit 
their circumstances and to maximise the value of any quality assurance initiative. More 
concretely, it aims to provide a practical introduction to the area of quality standards and 
quality assurance mechanisms and the key steps involved in their implementation in 
drug services and systems. Starting with an introduction to quality standards and their 
role in the broader area of quality assurance processes, the guide then presents in more 
detail six important steps to be considered by those intending to use and implement 
quality standards whether at the local, regional or national level. These reflection steps are 
based on public health intervention models, building on diagnosis, intervention selection, 
assessment and evaluation, and also draw on the model promoted in Health and social 
responses to drug problems: a European guide (EMCDDA, 2017a) and Evaluating drug 
policy: a seven-step guide to support the commissioning and managing of evaluations 
(EMCDDA, 2017b). 
While the primary audience for this guide is those responsible for commissioning, planning 
or providing quality assurance processes at the national or local level, it may also be of 
interest to recipients of interventions, service users or advocacy groups.
I Who can use quality standards and for what purpose?
There are a range of stakeholders who may be interested in implementing quality standards 
for drug demand reduction interventions. Some of the main ones and the uses they may 
have for quality standards are listed below.
Commissioners, planners or funders can use quality standards to: 
 ■ ensure that services and interventions meet quality requirements;
 ■ monitor services and interventions to ensure ongoing compliance with 
quality and safety;
 ■ ensure client or service user feedback is embedded into planning and 
provision;
 ■ ensure staff providing services and interventions meet quality 
requirements and are competent, well-managed and supported;
 ■ support services to embed quality assurance processes.  
Service providers can use quality standards to: 
 ■ audit, monitor and demonstrate service quality; 
 ■ actively find and address areas for improvement;
 ■ benchmark (if appropriate) minimal quality;
 ■ identify training needs for staff members.
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Individual practitioners can use quality standards to: 
 ■ be clear about the competence and practice required from them;
 ■ recognise their qualifications, training and skills;
 ■ ensure they are well-managed, supported and have professional 
development; 
 ■ contribute to a culture of continuous improvement. 
Recipients, clients, patients and their families and other stakeholders can use quality 
standards to: 
 ■ gain knowledge about the quality of services or interventions they can 
expect; 
 ■ make more informed choices about which interventions and services to 
access (if quality assurance results are publicly available);
 ■ use known mechanisms to raise concerns and complaints about 
interventions or services;
 ■ engage and contribute to quality assurance and improvement.  
Certification, accreditation, licencing, regulatory and inspectorate bodies can use quality 
standards to:
 ■ licence, certify or register interventions, services or practitioners;
 ■ ensure ongoing compliance with regulatory requirements through 
inspection or revalidation processes; 
 ■ identify abuse, unsafe and non-evidence-based practice, service deficits, 
as well as action required to improve – in line with the remit of the 
organisation;
 ■ identify priority areas for quality improvement in health and social care.
I Types of quality standards that apply to drug-related interventions
Quality standards are developed and published to support services and systems 
improvement, and they can be general or specific, voluntary or mandatory, national or 
local. National standards or mechanisms may be countrywide or devolved to federal, state, 
local or city levels. Many types of quality standards can apply to drug-related interventions. 
These may include general standards, for example, standards that cover all aspects of a 
health or education system, or they may be bespoke and specific to drug treatment or drug 
prevention.  
An analysis of country reports on quality assurance, provided by national focal points to the 
EMCDDA in 2019, indicated the vast majority of European countries have in place a range 
of standards that apply to drug-related interventions or services. In some countries, for 
example, standards are linked to service delivery and evaluations. In other countries, quality 
standards are a requirement for participation in competitions for service contracts, or they 
are used as instruments for service-level self-assessment. 
Many different types of quality standards exist, and they are used for a variety of purposes, 
all linked to the improvement of systems or service provision. Some standards are 
requirements that need to be fulfilled to be accredited. They can regulate the physical space 
and the facilities where a service is provided. Others cover the outcomes that a service 
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or a system is expected to achieve, the processes that should be implemented and the 
physical spaces where those processes take place. Some include recommendations for 
actions (and in this, they are similar to guidelines) and others are composed of aspirational 
statements to be operationalised in different contexts. Examples of formal or required 
standards include fire safety or infection control in drug use disorder treatment service 
premises; standards relating to staff qualifications or certification; national requirements to 
meet legislation to protect children and young people deemed at risk of harm; medicines 
management standards. 
Definitions used in this guide
Accreditation is the process by which an institution delivering a service is 
independently assessed for quality against pre-defined criteria and standards, which 
are set by the accrediting body. 
An audit is a systematic examination of an activity, process, data, records or 
environment. 
Certification is the formal attestation or confirmation of certain characteristics of an 
object, person or organisation. This confirmation is often, but not always, provided by 
some form of external review, education, assessment or audit. 
Evaluation is a process that critically examines a programme. It involves collecting 
and analysing information about a programme’s activities, characteristics and 
outcomes. Its purpose is to make judgements about a programme, to improve its 
effectiveness and to inform programming decisions.
Evidence-based intervention is a concept imported from the medical field, where 
evidence-based medicine is defined as ‘the conscientious, explicit, and judicious use 
of current best evidence in making decisions about the care of individual patients’ 
(Sackett et al., 1996). When applied to drug demand reduction, this refers to the use 
of scientific results to inform intervention decisions.
Guidelines are used to encourage the use of evidence-based interventions by 
providing practice recommendations that are based on appraisal, synthesis and 
grading of available evidence. Guidelines typically outline a plan of expected activity 
(which may be mandatory in some countries). They provide a guide to recommended 
practice, and may operate alongside standards, providing a benchmark against which 
to evaluate the quality of the services being delivered.
Quality assurance is a process which involves continuous monitoring and striving to 
improve quality and outcomes. The concept includes the assessment or evaluation 
of the quality of care; identification of problems or shortcomings in the delivery of 
care; design of activities to overcome these deficiencies; and follow-up monitoring to 
ensure effectiveness of corrective steps. Quality standards are one of the tools used 
in the quality assurance process. Based on the WHO definition, quality assurance 
systems in drug demand reduction focus on the extent to which drug-related 
interventions, services or systems improve outcomes. 
Quality standards are principles and sets of rules, often set by recognised national or 
international bodies, that may be used to implement interventions. A quality standard 
may be described as a statement of expected requirements. It can refer to content 
issues, processes or to structural aspects. Typically, the standards proposed in the 
health field are evidence-based, and provide clear and aspirational, yet measurable, 
statements related to content, processes or structural aspects of quality assurance, 
such as environment and staffing composition.
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I Quality standards in the national, European and international context 
The development and implementation of quality assurance in drug demand reduction 
is a priority in many European countries, and recent years have seen an increase in 
the proportion of countries that report having published guidelines and standards for 
interventions, and having set up accreditation systems for service provision. 
At the European level, the European drug prevention quality standards (EDPQS), developed 
by the European Prevention Standards Partnership, were published by the EMCDDA in 
2011. The Partnership reviewed, synthesised and consulted on existing evidence and 
standards in order to identify which quality standards should apply to drug prevention 
activities. 
Quality standards in drug demand reduction have also been a priority in the last two EU 
drug strategies and related action plans. The actions in the European drug strategy 2013-
2020 included a ‘study on the development of an EU framework for minimum quality 
standards and benchmarks in drug demand reduction’ (European Union, 2012). The EQUS 
project (Uchtenhagen and Schaub, 2011) developed a range of minimum quality standards 
for the European Commission, a selection of which were adopted in 2015 (see box below). 
The current EU drug action plan, 2021-2025 (European Union, 2021) calls, in Action 38, 
for services to be guided by the minimum quality standards for drug demand reduction 
interventions in the European Union. This publication is in response to that call.
The Cooperation programme between Latin America, the Caribbean and the European 
Union in drugs policies (COPOLAD) has developed a set of quality standards and criteria 
for drug demand reduction interventions, services and programmes (prevention, treatment, 
harm reduction and social integration) and elaborated them in collaboration with the 
EMCDDA, the Inter-American Drug Abuse Control Commission (CICAD), the Pan American 
Health Organisation (PAHO) and the United Nations Office on Drugs and Crime (UNODC).
European minimum quality standards
The EU minimum quality standards (Council of the European Union, 2015) include 16 
aspirational statements, allowing space for Member States to set their objectives and 
make progress at their own pace towards common goals. Countries are encouraged 
to operationalise them in line with their national strategies, and many interventions 
currently delivered at European or national level are based on the implementation 
of these standards. For example, for prevention, the standards clarify how the target 
population defines the type of prevention strategies to be put in place, and suggests 
that the analysis of the needs of these populations assists the selection of the most 
appropriate approach. The standards highlight the crucial role of training to build 
competences for professionals delivering prevention interventions. For treatment and 
social reintegration, the standards reinforce the centrality of patients and the need to 
respect their stage of preparedness for change as a basis to determine therapeutic 
approaches. In addition, the standards aim at ensuring voluntary access to treatment 
to all in need without any financial restrictions. To support the implementation of 
these quality standards, the European commission tasked the Civil Society Forum on 
Drugs with the publication of guidelines and recommendations for implementation, 
which was published recently (Civil Society Forum on Drugs, 2020).
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At the international level, the UNODC and World Health Organization (WHO) have 
supported the development of quality standards for both drug prevention and treatment. 
Their ‘International standards on drug use prevention’ (UNODC and WHO, 2018) describe 
evidence-based prevention interventions and policies, and the major components and 
features of an effective national drug prevention system. The UNODC/WHO ‘International 
standards for the treatment of drug use disorders’ focus on the provision of guidance and 
training to health professionals on developing standards and accreditation for services 
at the domestic level, to ensure that responses to drug use disorders are scientific and 
evidence-based and are delivered by qualified personnel. The UNODC developed and 
piloted quality assurance mechanisms for drug use disorder treatment for services 
and systems (Saenz et al., 2019), and following global field testing, the UNODC/WHO 
‘International standards for the treatment of drug use disorders’ were revised and 
relaunched in 2020, together with a suite of quality assurance tools.
I The quality standards implementation process
An overall goal of quality assurance is to create a cycle of continuous reflective practice and 
improvement. In this context, quality assurance mechanisms encompass the whole array of 
activities and documents that may be put in place to support the quality of interventions. In 
addition to quality standards, these may include, for example, evidence-based guidelines, 
paper or electronic checklists and reminders, training, inspections, audits and feedback, 
and surveys of client satisfaction.
Quality assurance mechanisms, including the use of quality standards, can help ensure 
that organisations are implementing or providing ‘best practice’ for patients, clients, 
staff and communities. Good quality drug demand reduction interventions, based on 
evidence and firmly located in human rights and ‘best practice’ can help improve people’s 
lives and life chances. Quality standards, professional training and the overall quality 
assurance mechanisms can help all of those involved in drug demand reduction have clear 
expectations of what will be provided, from planners and funders, to providers and those 
receiving interventions. However, drug-related interventions are not neutral, and those 
which are not based on evidence risk being ineffective and producing unwanted effects.
Similarly, it is widely accepted that staff lacking competence (qualifications, skills or 
knowledge) are likely to deliver poorer outcomes in a drug demand reduction initiative. 
Quality assurance processes can help expose and tackle abuse or maltreatment of 
clients or service users, unsafe or dangerous practice, non-evidence-based practice and 
organisational deficits that compromise service delivery.
One of the functions of quality assurance is embedding a culture of reflection and 
continuous improvement. However, quality assurance mechanisms are sometimes seen 
as additional bureaucratic activities for already busy individuals, services or systems. In 
reality, they do require additional work but, in the long run, they help professionals to work 
better and to improve practices and services. Quality assurance mechanisms encourage 
‘user involvement’, transparency and accountability and are proven methods of embedding 
effective practice.
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I Six steps to consider for implementing quality standards
The following section proposes six steps to consider when implementing quality assurance 
processes and standards. Depending on the scope of the quality standards project, some 
or all of the steps may be helpful; nevertheless, taken together, they outline a full cycle of 
continuous improvement. However, it is also possible to start at different points in the cycle, 
and especially for those already engaged in a quality assurance process, certain steps may 
already be complete. Similarly, some steps may be more or less important for different 
types of assessment, depending on whether the focus is, for example, a harm reduction 
intervention, a treatment service or a prevention system.
1. Diagnosis: what is the problem?
2. Scoping: what are the goals and who to involve? 
3. Mapping and selection: what standards apply and how can we verify 
them?
4. Assessment of systems and services: how to evaluate.
5. Drafting a plan and disseminating results: when, where, and to whom to 
communicate.
6. Preparing for the next cycle: how to ensure continuous evaluation.
FIGURE 1




Diagnosis: what is the problem 
the quality assurance project 
will address?
The initial diagnosis phase focuses on the identification of the problem that the quality 
assurance project will address. The problem diagnosis may use a range of analytic methods 
including analysis of service outcomes, the results of a client consultation (service level); 
the evaluation of a drugs strategy or a national health system performance (system level). 
Important questions here might include: What needs is the project responding to? What is it 
trying to achieve? Is there is a need for improvement in a particular service area or system?
Some possible answers are:
 ■ we need to respond to a problem (e.g. a service is outdated, does not 
attract young clients);
 ■ we need to improve service outcomes (e.g. reducing waiting lists, 
reducing drop out, improving compliance);
 ■ we need to pilot a quality assurance mechanism for a service;
 ■ we need to assess whether a programme has been correctly 
implemented;
 ■ we need to improve an existing quality assurance mechanism in an 
intervention, service or system;
 ■ we need to benchmark interventions against each other in relation to 
their quality. 
In some, hopefully rare cases, a quality assurance project can be initiated because there 
are complaints or concerns around serious issues, including for example abuse of clients 
or staff, or national laws being broken, or breaches of codes of professional practice. 
These cases can be the triggers for starting a process or may be discovered during the 
process. In both cases, immediate action may need to be taken. It is good practice to have 
a written protocol of actions to be taken if these issues are found, which is shared with the 
intervention, services or system managers prior to an assessment. If serious infractions are 
found, these have to be reported to the appropriate entities.
I What ‘level’ does the quality standards project relate to? 
During the initial diagnosis step, it is also important to have clarity about which level 
the project relates to. In other words: what is the level of the problem identified and that 
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the quality standards project will need to address? A framework was introduced with 
the European EQUS project (Uchtenhagen and Schaub, 2011), which outlined quality 
standards at the levels of intervention, service and system. 
The intervention level may include, for example, a psychosocial treatment such as a 
cognitive behavioural therapy programme or a drug prevention intervention. The service 
level might be, for example, an organisation providing a range of interventions such as a 
community drug service. System level could include, for example, a network of drug harm 
reduction, treatment and recovery services in a particular locality such as a city. 
It is important that the level of the quality assurance project matches the remit of the 
services or people involved. For example, service providers who want to examine quality 
issues associated with access to treatment should focus on the issues they control, such as 
waiting times or equality of access for the populations they serve. They are not responsible 
for access issues for the whole system.
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STEP 2
Scoping: what are the goals 
and who to involve?
Once there is a diagnosis of the problem and the needs to be addressed by the quality 
standards project are clarified, scoping will drive decisions on what leadership is required, 
who needs to be involved as key stakeholders, and the resources needed for the project. 
This step should conclude with the development of a concrete project plan.
I Leadership 
It is critical to success to have good leadership for the project at a sufficient level of 
responsibility. The project leadership will need to ensure good planning and project 
management; governance; permission or consent for the process; and fairness and 
transparency, particularly as resistance or challenge may be encountered. Project leaders 
will need to involve and motivate the partners (service manager, intervention manager or 
system leader), not least because they are likely to be responsible for improving the quality 
of their intervention, service or system. Projects may benefit from a project management 
team or steering group involving key stakeholders, including senior representatives, clients 
or ‘end participants’ of the interventions, services and systems.
I Key stakeholders
Stakeholder involvement is central to quality standards implementation. Stakeholders 
have different roles, levels of responsibility and may be involved in a number of ways, 
including involvement in the project management group or a project steering group; 
through consultation processes on standards and criteria or development of an assessment 
methodology; by participating in an assessment process itself (for example as subjects, 
assessors, expert patient or peer interviewers); as recipients of results; or by being expected 
to change their practice to make improvements. Key stakeholder groups may include 
policymakers, planners and funders; service provider staff; recipients, clients or patients; 
partner services and organisations; and, wider carer and community stakeholders.  
Table 1 shows the stakeholders that may need to be involved at different levels.
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I Resources
Adequate resources for the project should be secured and allocated against the project 
plan, whether the project is small (for example, a review of what quality standards apply to 
a service) or large (for example, a pilot project for a new process implemented in a range 
of services). It is important that the project has a realistic budget for its actions. Most 
projects separate the resources required for the evaluation phase from resources required 
if improvement action is required: this should be clear from the outset. While the availability 
of resources may vary greatly, depending on the country or context, it is important to 
remember that it is always possible to address and improve the quality of interventions.
I Project planning 
Once the scope is decided and the resources are secured, a detailed project plan should 
be developed. This may include aims, outcomes, desired outcome, project management 
arrangements, resources and a budget, the key steps with measurable milestones, who is 
responsible for each step and reporting arrangements/communications. It is important to 
allocate sufficient time for each step, as aspects of the project may be reliant upon other 
parties, for example, gaining ethical permission for assessments. Complex projects may 
also benefit from contingency and risk management plans. The project plan should be 
agreed upon with the project group and shared with key stakeholders.
TABLE 1
Stakeholders who may need to be involved  
Intervention level Service level System level 
• Clients or patients
• Patient advocacy body
• Intervention manager, staff
• Host service management
• Intervention funder or planner
• Staff ‘professional’ body 
• Clients or patients
• Patient advocacy body
• Carers, community 
representatives
• Lead clinician, staff
• Staff ‘professional’ body 




• Service funders or planners
• Service regulatory, 
accreditation or inspectorate 
body
• Clients, patients, carers









Mapping and selection: what 
standards apply and how can 
we verify them? 
At this stage, both the needs and scoping of the project are clear, and a project group has 
been set up to work on the implementation of quality standards. The next step is to decide 
which quality standards are most appropriate to use in the circumstances. As mentioned 
earlier, many quality standards are available for different purposes. 
A country or locality may have existing quality standards and mechanisms that apply to 
their staff, interventions, services or systems. Some of these standards are voluntary, as is 
the case for the European and international standards but others, especially at local level, 
may be mandatory. Exploring existing quality standards and mechanisms that might be 
applicable is a key step in establishing a quality assurance mechanism.
I Types of quality standards to consider
There may be numerous sets of quality standards that are potentially relevant for drug 
demand reduction interventions. Most countries will have some standards or quality 
assurance mechanisms that are applicable. These may include general standards or quality 
assurance mechanisms, for example, standards that cover all aspects of a health system 
or education provider standards, or they may be bespoke and specific to drug demand 
reduction. The range may include:
 ■ internationally recommended standards, such as the UNODC/WHO and 
European initiatives described earlier;
 ■ national standards or mechanisms, or those devolved to more local areas such 
as federal, state or provincial requirements;
 ■ standards or quality assurance mechanisms required as a condition of funding, 
for example, those required to receive state or health insurance funding;
 ■ requirements from state or regional accreditation, certification, licensing, 
registration or regulatory bodies; 
 ■ standards or quality assurance mechanisms related to the type of service 
or delivery base of the intervention, such as standards for all hospital-based 
services, school-based interventions, standards for residential rehabilitation 
units; 
 ■ standards related to human resources and staff, which may be funding 
requirements, legal requirements, or professional body standards such as 
qualifications/certification; 
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 ■ statutory or legal requirements and standards related to certain types of 
activities, such as financial conduct ‘rules’, health and safety standards 
and medico-legal standards (for example consent);
 ■ voluntary standards and quality assurance mechanisms which may have 
formal recognition (such as the ISO standards and ‘kite marks’) or are a 
basis of internal audit.
Table 2 can be used to map and document which existing quality standards and quality 
assurance mechanisms may be relevant to your project.
TABLE 2
Mapping quality standards and quality assurance mechanisms relevant to the project


















Assessment of systems and 
services: how to evaluate
After having identified needs and having decided on the scope of standards 
implementation and having mapped the existing or suitable standards, and chosen those 
most appropriate, it is possible to proceed towards the assessment of services or systems 
(Step 4). This step consists of checking whether a system or a service meets the standards 
selected or needs to be improved. A key element to successfully completing this step is 
establishing consensus on the data required and choice of verification method.
I Deciding what information is required
It is advisable to carefully consider the information required for assessment of each quality 
standard or criterion that has been selected. Common forms of data utilised for assessing 
quality against standards and criteria in drug demand reduction interventions include the 
following.
 ■ Service or programme documents: such as manuals, policies, 
procedures, protocols for interventions, planning documents, financial 
documents or accounts, service information, client or consumer 
information in order to document and measure the processes in place.
 ■ Monitoring, performance or outcomes data: such as data on access, for 
example waiting times or the number of people on a waiting list, number 
of people or clients receiving a particular intervention or services, 
key indicator data; outcome data; patient or client complaints data; 
monitoring data on serious incidents or ‘never events’. 
 ■ Client or service user feedback: such as data on satisfaction, the quality 
or appropriateness of an intervention; feedback on staff competency 
at delivering an intervention or the quality of a therapeutic relationship; 
feedback on environments or setting; suggestions for improving 
interventions or services. 
 ■ Staff or manager feedback: on issues such as staff and managerial 
competence (skills, knowledge and qualifications), training required, 
service or intervention delivery, suggestions for improvement.  
 ■ Information collected by audits: such as patient records or case 
note audits, staff record audits, audits of compliance with medicines 
management standards.
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 ■ Feedback from key stakeholders: such as organisations operating in 
partnership with the service being assessed, funders, members of the 
public or community groups with an involvement in the services or 
intervention, carers or those with parental responsibility for clients or 
recipients of interventions.
I Selecting the methods for data collection
Once a project group has reviewed what data it requires to review each quality standard, 
decisions should be made about the methods for collecting each piece of data. A range of 
methods may be used to collect and collate or analyse data for a quality assurance project. 
Common methods are:
 ■ review of a documentation; 
 ■ collating and analysing service monitoring or performance data;
 ■ client or service user surveys or focus groups;
 ■ interviews with service managers;
 ■ staff surveys or interviews; 
 ■ visual inspections; 
 ■ observations of intervention delivery;
 ■ surveys or focus groups with key stakeholders.
Supporting information is generally either gathered by an external team or by the service 
or organisation itself (management or clinical or administrative staff tasked with a quality 
assurance role).
If the process is implemented by the organisation itself, the steps below may be followed. 
 ■ Ensure ethical approval requirements have been met and written 
consent forms accompany surveys (where required). 
 ■ Train assessors in the quality assurance process; gaining consent; data-
collection in line with methods used and initial scoring. It may be helpful 
to create an ‘expert assessor or audit team’ to build organisational 
capacity in quality assurance, if this is undertaken by more than one 
person. 
 ■ It is good practice to create and distribute communications materials 
about the quality assurance process (including the standards that 
should be met) for key stakeholders – particularly clients or end-users 
and staff.
 ■ Gather data according to the plan and resources. 
 ■ Collate information and data in a format that allows standards and 
criteria to be scored.
Especially in the case of international standards that may consist of aspirational statements 
and are not accompanied by sources of data and indicators of achievement, this step will 
consist of operationalising the standards in order to assess whether they are met or not.
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I Verification and scoring
Various possible ways are viable to assess the standards implementation; some are more 
rigorous and complex than others. Verification tools are available to support this step. These 
tools allow assessment as to whether a system or a service has already met the standards 
or if further actions are needed to improve the quality. Simple verification tools, for example 
based on Excel spreadsheets, can be used to compare data currently recorded (see the 
example in Table 3).
More complex verification tools can use some scoring systems where different levels of 
implementation are attributed different scores, these can use numerical or colour schemes. 
One possible verification tool is a ‘scoring framework’ using measurements methods. 
There are many examples of scoring frameworks in quality assurance mechanisms in both 
mainstream and drug use disorder treatment and prevention systems. Many frameworks 
use colours or numbers which are understood by many cultures and countries. Some 
frameworks have more granularity – such as a 5-point Likert scale that allows for a greater 
variety of scoring responses (see Table 4).  
This is an area which requires some careful consideration by the assessment team. The 
choice of the verification tool should be influenced by the level of sophistication and 
resources available to the project, and should be clear and unambiguous. Whatever 
TABLE 3 
Example of a standard, criteria and data taken from international consensus standards 
2020
Standard M6: The service has a patient records system that facilitates treatment and care
Ref Criteria Requirement Scoring Verification
M6a
The service has a 
comprehensive 
patient record system




electronic patient record 
system
Partially met
Partial paper or electronic 
patient record system
Not Met
No paper or electronic patient 
record system
TABLE 4
Examples of scoring frameworks
Framework Scale
3-point Likert scale Not met Partially 
met
Met
BRAG scale  
blue, red, amber, green
Not 
applicable
Not met Partially met Met
5-point Likert scale – 
descriptive
Very poor Poor Fair Good Excellent
5-point Likert scale – 
numeric
1 2 3 4 5
Care Quality 
Commission
Inadequate Requires improvement Good Outstanding
   
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technique is used to establish scoring, it is essential that there is clear guidance on how to 
proceed. This is important for both the service, intervention or system being assessed and 
for the assessors. 
I Important considerations during the assessment phase
Whether compliance with the selected quality standards has been evaluated internally 
or by an external partner, a good and constructive communication flow between the 
assessors and those being assessed is critical. Needs for improvement have to be seen as 
opportunities for all – both clients and professionals – rather than as judgement or blame 
for the professionals only. Although the managers of the intervention, service or system 
being assessed will ultimately be responsible for quality improvement and will be asked to 
keep implementing a cycle of continuous improvement, this effort has to be perceived as a 
co-production for the common interest. 
Apprehension and fear are normal reactions to scrutiny – particularly if that scrutiny may 
impact on people’s jobs or work practice. If managers are fearful, feel ‘blamed’ for poor 
quality or are resistant to change, it may be more difficult to get them to embrace a culture 
of reflective practice and continuous improvement. 
On the other hand, a culture of understanding and ‘no blame’ is more likely to encourage 
results to be accepted and responsibility to be taken for improvement. Assessors should 
be skilled in working with resistance and barriers and should encourage a culture of 
pragmatism and responsibility.  
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STEP 5
Drafting an improvement plan 
and disseminating results: 
when, where and to whom to 
communicate
Following assessment and scoring by the assessors, the results should be presented as a 
written report. Often these reports feature some ‘scorecard’ or a summary sheet of scores, 
using colours and numbers, that is easy to understand. Nevertheless, the most important 
part of the report is the recommendations for improvements. These need to be based on a 
dialogue with key stakeholders on feasibility and include concrete steps for improvements. 
The results of the quality assurance assessment should be communicated to the managers 
of the intervention, service or system. If the quality assurance process is new or the results 
are poor or controversial, it may be beneficial to present and discuss results in a meeting. 
If urgent and serious issues have been identified during an assessment, a formal process 
should be triggered as soon as feasible to ensure these issues are addressed without delay. 
In any case, it is considered good practice to allow those receiving the assessment 
report some time to digest the report and raise queries, suggest factual corrections or 
dispute aspects of the assessment. Most formal quality assurance mechanisms will not 
accept additional data after the assessment – as this may have been developed after the 
assessment. A clear process of dispute resolution is required, especially in formal quality 
assurance processes that may influence funding or service continuation. 
The final report should be formally agreed upon among the stakeholders and the assessors, 
as it forms the basis of subsequent actions to improve quality. Ideally, the results of the 
assessment should be made available to staff and clients and all those affected by the 
intervention, service or system evaluated.
The report will need to be followed by an implementation plan of actions to improve or 
consolidate the quality standards.
I The improvement plan and actions for prioritisation
Normally, the areas for improvement are those judged as not meeting standards. 
Nevertheless, they cannot be automatically translated into actions, without a consensus 
on priorities. Managers should be aware that selection of areas for improvement would 
normally include prioritising those that are critical to upholding human rights, client 
safety, staff safety or treatment or areas that are required by law or professional practice 
guidelines. If there are many areas for improvement, prioritisation can help focus limited 
resources on the most important issues to address.   
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In addition, when discussing the results of the assessment with the stakeholders, it is 
important to identify the reasons for not meeting some of the standards. For example, a 
common issue is deciding whether a score is due to a lack of monitoring or recording of 
practice (for example a lack of detail in monitoring or patient records) or actual deficits in 
practice. 
For purposes of documentation, decisions on new actions to be taken can be added to the 
verification tool (see example in Table 5). The improvement plan can also include specific 
details, such as the target or outcome of the improvement, the resources required for the 
improvement to be made, who is responsible, when the improvement target will be met and 
when the re-audit will occur.
The improvement plan should be as practical as possible, with SMART objectives (specific, 
measurable, attainable, relevant and timely). Setting dates for the re-audit to check for 
improvement is an important part of the process, which can be negotiated between the 
stakeholders and the assessors.
TABLE 5
Example of standards scoring with actions for improvement
Standard M6: The service has a patient records system that facilitates treatment and care
Ref Criteria Requirement Scoring Verification Actions to be taken 
(Step 5)
M6a









electronic patient record system
No further actions 
needed
Partially met
Partial paper or electronic 
patient record system
Incorporate the missing 
parts into the system
Not Met
No paper or electronic patient 
record system




Preparing for the next cycle: how 
to ensure continuous evaluation
An overall goal for a quality assurance project is to enable a culture of continuous 
improvement to become embedded in services and systems. In this context, implementing 
one-off assessments will be of limited value in improving quality over a period of time. 
The main focus for this final step is ensuring that a cycle or process of continuous 
evaluation is in place. This will involve planning and preparing for the next cycle of 
interventions.
Having a culture of reflective practice and continuous improvement is a fundamental 
part of most healthcare and social services delivery. This is often embedded through 
governance mechanisms. Clinical governance, for example, is a mechanism by which 
health organisations are accountable for continuously monitoring and striving to improve 
the quality of their services. This ensures that standards are met, there is adherence to 
evidence-based guidelines and that clinical excellence is encouraged. 
A culture of reflective practice and continuous improvement is also a core requirement 
for many professional staff groups such as doctors, nurses, pharmacists and teachers. 
Most professional staff are required to meet and maintain some standards of practice, 
demonstrated through gaining qualifications or professional certification (training); they are 
duty-bound to engage in supervision and continuous professional development; and they 
are assessed or revalidated regularly by regulatory, accreditation or inspectorate bodies to 
ensure quality of practice.  
Once the report is disseminated and plans for improvement are being implemented, it 
might be helpful to maintain momentum by convening all your stakeholders to provide 
an update on the ongoing process and initiate discussions on the priorities for the next 
round of quality assurance and review. It is very likely that the quality assurance cycle 
identified new needs, for example to invest more in training and knowledge sharing and the 
implementation of new technological solutions. As a result, a follow-up quality standards 
project may have a different focus to the current one.
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This publication provides a practical introduction to the area of quality standards and quality 
assurance mechanisms and the key steps involved in their implementation in drug services 
and systems. The primary audience for this guide is those responsible for commissioning, 
planning or providing quality assurance processes at the national or local level. It may also 
be of interest to recipients of interventions, service users or advocacy groups.
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